Spyre Therapeutics (SYRE) Capital Expenditures (2015 - 2023)
Spyre Therapeutics (SYRE) posted Capital Expenditures of -$2.1 million for Q3 2023, down 206800.0% on a QoQ basis from $1000.0 in Q3 2022, and down 206800.0% year-over-year from N/an in Q3 2022.
Spyre Therapeutics (SYRE) Capital Expenditures (2015 - 2023) Analysis & Trends
Spyre Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at -$2.1 million for Q3 2023.
- Quarterly Capital Expenditures fell 206800.0% year-over-year to -$2.1 million in Q3 2023, while the trailing twelve-month figure through Dec 2023 was -$2.1 million (down 5536.84% YoY) and the FY2022 annual result came in at $38000.0, down 93.37% from the prior year.
- Capital Expenditures was -$2.1 million for Q3 2023 at Spyre Therapeutics, down from $1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.7 million in Q2 2020 and bottomed at -$2.1 million in Q3 2023.
- A 5-year average of $227142.9 and a median of $105500.0 in 2019 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2020 — Capital Expenditures soared 2807.02% — and 2023, when it sank 206800.0%.
- Spyre Therapeutics' Capital Expenditures stood at $38000.0 in 2019, then soared by 2531.58% to $1.0 million in 2020, then plunged by 90.7% to $93000.0 in 2021, then sank by 98.92% to $1000.0 in 2022, then sank by 206800.0% to -$2.1 million in 2023.
- Business Quant data shows SYRE's Capital Expenditures at -$2.1 million in Q3 2023, $1000.0 in Q3 2022, and $37000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -2.07 Mn |
| Sep 30, 2023 | -2.07 Mn |
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Sep 30, 2021 | 93,000.00 |
| Sep 30, 2021 | 93,000.00 |
| Jun 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 30,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Dec 31, 2020 | 1.00 Mn |
| Dec 31, 2020 | 1.00 Mn |
| Sep 30, 2020 | 566,000.00 |
| Sep 30, 2020 | 566,000.00 |
| Jun 30, 2020 | 1.66 Mn |
| Jun 30, 2020 | 1.66 Mn |
| Mar 31, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.06 Mn |